Klaria Pharma (KLAR) Q4 2025 earnings summary

Executive summary

• Net sales increased to 9.0 MSEK for the full year 2025, up from 2.2 MSEK year-over-year, but Q4 net sales were 0 MSEK compared to 1.1 MSEK in Q4 2024.

• Full-year loss after tax improved to -38.9 MSEK from -47.7 MSEK year-over-year; Q4 loss after tax was -8.4 MSEK, an improvement from -15.6 MSEK in Q4 2024.

• Major milestones included the start of production and preparations for the European launch of Sumatriptan Alginate Film, and a positive patent opinion extending exclusivity to 2045.

• Strategic business development accelerated with BDO to explore licensing and partnership opportunities in new markets.

Financial highlights

• Net sales for 2025: 9.0 MSEK (2024: 2.2 MSEK); Q4: 0 MSEK (Q4 2024: 1.1 MSEK).

• R&D expenses for 2025: 20.1 MSEK (2024: 22.1 MSEK); Q4: 4.8 MSEK (Q4 2024: 9.3 MSEK).

• Profit after tax for 2025: -38.9 MSEK (2024: -47.7 MSEK); Q4: -8.4 MSEK (Q4 2024: -15.6 MSEK).

• Cash flow from operating activities for 2025: -35.0 MSEK (2024: -11.9 MSEK); Q4: -2.4 MSEK (Q4 2024: 1.3 MSEK).

• Cash and cash equivalents at year-end: 0.3 MSEK (2024: 0.6 MSEK).

Outlook and guidance

• Initial launch of Sumatriptan Alginate Film in Germany, Spain, and Italy planned for 2026, with further European expansion in 2027.

• Focus on securing additional licensing and partnership agreements in key global markets, including the US, Middle East, South America, and Asia-Pacific.

• Patent protection for Sumatriptan Alginate Film expected to extend to 2045, enhancing long-term market exclusivity.